1. Conclude that acute myeloid leukemia is a heterogeneous disease and that the distinct mutations predict treatment outcome.

2.  Identify how oncogenes may become activated by hijacked enhancers in leukemia.

3.  Explain how to generate enhancer hijacking models and apply genome editing technology to uncover regulators of aberrant gene expression in cancer cells.

Zoom meeting info:


Session date: 
02/16/2022 - 8:00am to 9:00am CST
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report
Dr. Ruud Delwel